These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22998551)

  • 21. Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy.
    Ondeyka JG; Zink DL; Young K; Painter R; Kodali S; Galgoci A; Collado J; Tormo JR; Basilio A; Vicente F; Wang J; Singh SB
    J Nat Prod; 2006 Mar; 69(3):377-80. PubMed ID: 16562839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metalloenzyme inhibitors for the treatment of Gram-negative bacterial infections: a patent review (2009-2012).
    Supuran CT; Carta F; Scozzafava A
    Expert Opin Ther Pat; 2013 Jul; 23(7):777-88. PubMed ID: 23458841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enoyl acyl carrier protein reductase inhibitors: a patent review (2006 - 2010).
    Lu X; Huang K; You Q
    Expert Opin Ther Pat; 2011 Jul; 21(7):1007-22. PubMed ID: 21651455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of C(7) modified chrysin derivatives designing to inhibit beta-ketoacyl-acyl carrier protein synthase III (FabH) as antibiotics.
    Li HQ; Shi L; Li QS; Liu PG; Luo Y; Zhao J; Zhu HL
    Bioorg Med Chem; 2009 Sep; 17(17):6264-9. PubMed ID: 19664929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacterial fatty acid metabolism in modern antibiotic discovery.
    Yao J; Rock CO
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Nov; 1862(11):1300-1309. PubMed ID: 27668701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of FabH/FabF inhibitors from natural products.
    Young K; Jayasuriya H; Ondeyka JG; Herath K; Zhang C; Kodali S; Galgoci A; Painter R; Brown-Driver V; Yamamoto R; Silver LL; Zheng Y; Ventura JI; Sigmund J; Ha S; Basilio A; Vicente F; Tormo JR; Pelaez F; Youngman P; Cully D; Barrett JF; Schmatz D; Singh SB; Wang J
    Antimicrob Agents Chemother; 2006 Feb; 50(2):519-26. PubMed ID: 16436705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domain.
    Zeng XF; Li WW; Fan HJ; Wang XY; Ji P; Wang ZR; Ma S; Li LL; Ma XF; Yang SY
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4742-4. PubMed ID: 21752639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacterial beta-ketoacyl-acyl carrier protein synthase III (FabH): an attractive target for the design of new broad-spectrum antimicrobial agents.
    Castillo YP; Pérez MA
    Mini Rev Med Chem; 2008 Jan; 8(1):36-45. PubMed ID: 18220983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New antibacterial agents: patent applications published in 2011.
    Keating TA; Lister T; Verheijen JC
    Pharm Pat Anal; 2014 Jan; 3(1):87-112. PubMed ID: 24354981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel thiazole derivatives: a patent review (2008 - 2012; Part 1).
    Leoni A; Locatelli A; Morigi R; Rambaldi M
    Expert Opin Ther Pat; 2014 Feb; 24(2):201-16. PubMed ID: 24215328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III (FabH) as potential antibacterial agents.
    Shi L; Fang RQ; Zhu ZW; Yang Y; Cheng K; Zhong WQ; Zhu HL
    Eur J Med Chem; 2010 Sep; 45(9):4358-64. PubMed ID: 20557983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A combined approach of docking and 3D QSAR study of beta-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors.
    Ashek A; Cho SJ
    Bioorg Med Chem; 2006 Mar; 14(5):1474-82. PubMed ID: 16275103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quinoxaline derivatives: a patent review (2006--present).
    González M; Cerecetto H
    Expert Opin Ther Pat; 2012 Nov; 22(11):1289-302. PubMed ID: 22971178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel nitric oxide synthase inhibitors: a patent review.
    Joubert J; Malan SF
    Expert Opin Ther Pat; 2011 Apr; 21(4):537-60. PubMed ID: 21338328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
    Seefeld MA; Miller WH; Newlander KA; Burgess WJ; DeWolf WE; Elkins PA; Head MS; Jakas DR; Janson CA; Keller PM; Manley PJ; Moore TD; Payne DJ; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Uzinskas IN; Wallis NG; Huffman WF
    J Med Chem; 2003 Apr; 46(9):1627-35. PubMed ID: 12699381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional expression of Francisella tularensis FabH and FabI, potential antibacterial targets.
    Wen L; Chmielowski JN; Bohn KC; Huang JK; Timsina YN; Kodali P; Pathak AK
    Protein Expr Purif; 2009 May; 65(1):83-91. PubMed ID: 19095065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
    Heath RJ; White SW; Rock CO
    Appl Microbiol Biotechnol; 2002 May; 58(6):695-703. PubMed ID: 12021787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New antibacterial agents: patent applications published in 2010.
    Stokes SS; Morningstar M; Kocis H; Verheijen JC
    Pharm Pat Anal; 2012 Nov; 1(5):601-20. PubMed ID: 24236928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies.
    Wang X; Lin J; Chen Y; Zhong W; Zhao G; Liu H; Li S; Wang L; Li S
    Bioorg Med Chem; 2009 Mar; 17(5):1898-904. PubMed ID: 19223187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.